Abstract
Sch 21420, the 1-N-HAPA derivative of gentamicin B, has been compared to gentamicin, tobramycin and amikacin in a variety of in vitro and in vivo tests. Based on studies with a large number of sensitive and resistant bacteria, it was shown that Sch 21420 has a spectrum and potency essentially the same as that of amikacin. Serum levels in mice, rats, and dogs are similar to those of other aminoglycosides. Sch 21420 was found to be markedly less toxic than amikacin in chronic renal function tests in rats and thus appears to have an advantageously improved therapeutic index compared to amikacin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
